


**Business Alliance Agreement to Expand Contract Synthesis Services
for Glycan-Modified Oligonucleotides
— Hokkaido System Science Launches Contract Synthesis Services
Using KH Neochem's Glycans —**

KH Neochem Co., Ltd. hereby announces that it has entered into a business alliance agreement with Hokkaido System Science Co., Ltd. to expand contract synthesis services for glycan-modified oligonucleotides and promote related sales activities at Hokkaido System Science.



1. Background to the Business Alliance

In recent years, nucleic acid therapeutics^{*1} have emerged as a next-generation drug modality, and research and development involving siRNA, antisense oligonucleotides, and other technologies have accelerated worldwide. At the same time, establishing efficient drug delivery systems (DDS) to target tissues remains a key challenge for the practical application of nucleic acid therapeutics.

Glycan-based targeting technologies have the potential to enhance the selective delivery of therapeutics to specific tissues. This growing interest in targeted delivery is driving increased demand for research and development involving glycan-modified oligonucleotides.

2. Details of the Business Alliance

Building on its long-standing expertise in advanced organic synthesis, KH Neochem provides high-purity, homogeneous glycans essential for pharmaceutical development. The company offers integrated support throughout the development process, from structural design, synthesis, and evaluation to scale-up manufacturing.

Hokkaido System Science, meanwhile, has operated an oligonucleotide synthesis business for more than 30 years. In addition to contract synthesis services for DNA, RNA, and various modified oligonucleotides, it provides CRDMO^{*2} services supporting nucleic acid therapeutics from research and development through manufacturing.

Under this alliance, the companies will leverage their respective technologies and expertise in glycans and oligonucleotides. Hokkaido System Science will launch contract synthesis services for oligonucleotides modified with KH Neochem's glycans.

3. Future Direction

Through this alliance, KH Neochem will support Hokkaido System Science in expanding its service lineup for glycan-modified oligonucleotides, while contributing more broadly to the development of therapeutics through the application of glycan technologies.

*1 Nucleic acid therapeutics: Pharmaceuticals that use nucleic acids such as DNA and RNA to regulate the expression or function of genes associated with disease.

*2 CRDMO: Contract Research, Development and Manufacturing Organization

Company Profiles

Company Name	KH Neochem Co., Ltd.	Hokkaido System Science Co., Ltd.
Location	2-3-1 Nihonbashi-Muromachi, Chuo-ku, Tokyo	2-1 Shinkawa-nishi 2-1, Kita-ku, Sapporo, Hokkaido
Established	December 2010 (Kyowa Yuka Co., Ltd., the predecessor company, was established in November 1966)	September 1988
Representative	President and CEO, Michio Takahashi	President, Yukio Mizutani
Capital	JPY 8,855 million	JPY 30 million
Business Activities	Research, manufacture, and sale of various petrochemical products	Research support services (gene-related, protein-related, and biochemistry fields, and collaborative research)
Corporate Website	https://www.khneochem.co.jp/	https://hssnet.co.jp/



About KH Neochem's Glycans

Toward the realization of VISION 2030, KH Neochem has designated Environment, Healthcare, and Electronics as its strategic domains and is working to create new businesses. In the Healthcare domain, the company has focused on the potential of glycans, which are biomolecules, and has developed proprietary glycan and manufacturing technologies.

To further accelerate value creation from glycans, KH Neochem collaborates with biotechnology companies possessing advanced technologies to conduct proof-of-concept studies in the biopharmaceutical field. By combining the proprietary technologies of these companies with its glycan technologies, KH Neochem aims to promote the practical application of glycans and maximize the value of its glycan and manufacturing technologies.

KH Neochem's GlyMuch™ Glycans

<https://www.khneochem.co.jp/solution/glycan/>

About KH Neochem (As of December 31, 2025)

Company Name	KH Neochem Co., Ltd.	
Representative	President and CEO, Michio Takahashi	
Established	December 2010 (Kyowa Yuka Co., Ltd., the predecessor company, was established in November 1966)	
Capital	JPY 8,855 million	
Head Office	2-3-1 Nihonbashi-Muromachi, Chuo-ku, Tokyo	
Employees	863 (consolidated)	
Business Activities	Research, manufacture, and sale of various petrochemical products	
Main Product Categories	Performance materials (raw materials for refrigeration lubricants and cosmetics, etc.) Electronic materials (high-purity solvents for semiconductors and flat-panel displays, etc.) Basic chemicals (solvents for paints and inks, and raw materials for plasticizers, etc.)	
Group Companies	Kurogane Kasei Co., Ltd. / Kurogane Fines Co., Ltd. / KH Neochem Americas, Inc. / Chenghua (Shanghai) Trading Co., Ltd.	
History	1948	Kyowa Sangyo Co., Ltd. (later Kyowa Hakko Kogyo Co., Ltd.) became the first company in Japan to use fermentation technology to begin large-scale production of acetone and butanol from molasses.
	1949	Kyowa Hakko Kogyo Co., Ltd. was established (currently Kyowa Kirin Co., Ltd.).
	1966	Kyowa Yuka Co., Ltd. was established as a chemicals manufacturing subsidiary of Kyowa Hakko Kogyo Co., Ltd.
	2004	Kyowa Hakko Kogyo Co., Ltd.'s chemicals business integrated into Kyowa Yuka Co., Ltd., forming Kyowa Hakko Chemical Co., Ltd.
	2011	Kyowa Hakko Chemical Co., Ltd. became independent from the Kyowa Hakko Kirin Co., Ltd. group (currently Kyowa Kirin Co., Ltd.).
	2012	Company name changed from Kyowa Hakko Chemical Co., Ltd. to KH Neochem Co., Ltd.
	2016	Listed on the First Section of the Tokyo Stock Exchange.
	2018	VISION 2030 formulated.

	2019	KH i-Lab open innovation center established.
	2022	Transferred to the Prime Market following the Tokyo Stock Exchange market restructuring.
	2022	Entered a capital and business alliance with GlycoTechnica Ltd.
	2024	Capital and business alliance with Veneno Technologies.

Contact Information

KH Neochem Co., Ltd., Innovation Strategy
TEL: +81-3-3510-3600

Hokkaido System Science Co., Ltd.
TEL: +81-11-768-5901 E-mail: kikaku@hssnet.co.jp

Media Inquiries

KH Neochem Co., Ltd., Public Relations & IR
TEL: +81-3-3510-3579
FAX: +81-3-3510-3571
2-3-1 Nihonbashi-Muromachi, Chuo-ku, Tokyo
<https://www.khneochem.co.jp/>

Hokkaido System Science Co., Ltd.
TEL: +81-11-768-5901
FAX: +81-11-768-5951
2-1 Shinkawa-nishi 2-1, Kita-ku, Sapporo, Hokkaido
<https://hssnet.co.jp/>